Search

Your search keyword '"Zent, Clive"' showing total 48 results
Start Over Author "Zent, Clive" Publisher wiley
48 results on '"Zent, Clive"'

2. Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis

Author

Epperla, Narendranath, primary, Zhao, Qiuhong, additional, Anghelina, Mirela, additional, Neal, Jasmine, additional, Blachly, James S., additional, Rogers, Kerry A., additional, Lozanski, Gerard, additional, Oakes, Christopher C., additional, Bhat, Seema A., additional, Zent, Clive S., additional, Banerji, Versha, additional, Grever, Michael, additional, and Andritsos, Leslie A., additional

Published
2023
Full Text
View/download PDF

7. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

Author

Mato, Anthony R., primary, Roeker, Lindsey E., additional, Allan, John N., additional, Pagel, John M., additional, Brander, Danielle M., additional, Hill, Brian T., additional, Cheson, Bruce D., additional, Furman, Richard R., additional, Lamanna, Nicole, additional, Tam, Constantine S., additional, Handunnetti, Sasanka, additional, Jacobs, Ryan, additional, Lansigan, Frederick, additional, Bhavsar, Erica, additional, Barr, Paul M., additional, Shadman, Mazyar, additional, Skarbnik, Alan P., additional, Goy, Andre, additional, Beach, Douglas F., additional, Svoboda, Jakub, additional, Pu, Jeffrey J., additional, Sehgal, Alison R., additional, Zent, Clive S., additional, Tuncer, Hande H., additional, Schuster, Stephen J., additional, Pickens, Peter V., additional, Shah, Nirav N., additional, Rhodes, Joanna, additional, Ujjani, Chaitra S., additional, and Nabhan, Chadi, additional

Published
2018
Full Text
View/download PDF

11. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

Author

Zent, Clive S., primary, Victoria Wang, Xin, additional, Ketterling, Rhett P., additional, Hanson, Curtis A., additional, Libby, Edward N., additional, Barrientos, Jacqueline C., additional, Call, Timothy G., additional, Chang, Julie E., additional, Liu, Jane J., additional, Calvo, Alejandro R., additional, Lazarus, Hillard M., additional, Rowe, Jacob M., additional, Luger, Selina M., additional, Litzow, Mark R., additional, and Tallman, Martin S., additional

Published
2016
Full Text
View/download PDF

12. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

Author

Zent, Clive S., primary, Taylor, Ronald P., additional, Lindorfer, Margaret A., additional, Beum, Paul V., additional, LaPlant, Betsy, additional, Wu, Wenting, additional, Call, Timothy G., additional, Bowen, Deborah A., additional, Conte, Michael J., additional, Frederick, Lori A., additional, Link, Brian K., additional, Blackwell, Sue E., additional, Veeramani, Suresh, additional, Baig, Nisar A., additional, Viswanatha, David S., additional, Weiner, George J., additional, and Witzig, Thomas E., additional

Published
2014
Full Text
View/download PDF

13. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines

Author

Call, Timothy G., primary, Norman, Aaron D., additional, Hanson, Curtis A., additional, Achenbach, Sara J., additional, Kay, Neil E., additional, Zent, Clive S., additional, Ding, Wei, additional, Cerhan, James R., additional, Rabe, Kari G., additional, Vachon, Celine M., additional, Hallberg, Emily J., additional, Shanafelt, Tait D., additional, and Slager, Susan L., additional

Published
2014
Full Text
View/download PDF

14. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis

Author

Greipp, Patricia T., primary, Smoley, Stephanie A., additional, Viswanatha, David S., additional, Frederick, Lori S., additional, Rabe, Kari G., additional, Sharma, Ruchi G., additional, Slager, Susan L., additional, Van Dyke, Daniel L., additional, Shanafelt, Tait D., additional, Tschumper, Renee C., additional, and Zent, Clive S., additional

Published
2013
Full Text
View/download PDF

15. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

Author

Shanafelt, Tait, primary, Lanasa, Mark C., additional, Call, Timothy G., additional, Beaven, Anne W., additional, Leis, Jose F., additional, LaPlant, Betsy, additional, Bowen, Deborah, additional, Conte, Michael, additional, Jelinek, Diane F., additional, Hanson, Curtis A., additional, Kay, Neil E., additional, and Zent, Clive S., additional

Published
2013
Full Text
View/download PDF

16. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

Author

Parikh, Sameer A., primary, Rabe, Kari G., additional, Call, Timothy G., additional, Zent, Clive S., additional, Habermann, Thomas M., additional, Ding, Wei, additional, Leis, Jose F., additional, Schwager, Susan M., additional, Hanson, Curtis A., additional, Macon, William R., additional, Kay, Neil E., additional, Slager, Susan L., additional, and Shanafelt, Tait D., additional

Published
2013
Full Text
View/download PDF

17. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

Author

Witzig, Thomas E., primary, Wiseman, Gregory A., additional, Maurer, Matthew J., additional, Habermann, Thomas M., additional, Micallef, Ivana N.M., additional, Nowakowski, Grzegorz S., additional, Ansell, Stephen M., additional, Colgan, Joseph P., additional, Inwards, David J., additional, Porrata, Luis F., additional, Link, Brian K., additional, Zent, Clive S., additional, Johnston, Patrick B., additional, Shanafelt, Tait D., additional, Allmer, Cristine, additional, Asmann, Yan W., additional, Gupta, Mamta, additional, Ballas, Zuhair K., additional, Smith, Brian J., additional, and Weiner, George J., additional

Published
2013
Full Text
View/download PDF

18. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Kourelis, Taxiarchis V., primary, Gertz, Morie, additional, Zent, Clive, additional, Lacy, Martha, additional, Kyle, Robert, additional, Kapoor, Prashant, additional, Zeldenrust, Steven, additional, Buadi, Francis, additional, Witzig, Thomas, additional, Hayman, Suzanne, additional, Lust, John, additional, Russell, Stephen, additional, Lin, Yi, additional, Rajkumar, Vincent S., additional, Kumar, Shaji, additional, Leung, Nelson, additional, Dingli, David, additional, and Dispenzieri, Angela, additional

Published
2013
Full Text
View/download PDF

19. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia

Author

Shanafelt, Tait D., primary, Call, Timothy G., additional, Zent, Clive S., additional, Leis, Jose F., additional, LaPlant, Betsy, additional, Bowen, Deborah A., additional, Roos, Michelle, additional, Laumann, Kristina, additional, Ghosh, Asish K., additional, Lesnick, Connie, additional, Lee, Mao-Jung, additional, Yang, Chung S., additional, Jelinek, Diane F., additional, Erlichman, Charles, additional, and Kay, Neil E., additional

Published
2012
Full Text
View/download PDF

20. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

Author

Charbonneau, Bridget, primary, Maurer, Matthew J., additional, Fredericksen, Zachary S., additional, Zent, Clive S., additional, Link, Brian K., additional, Novak, Anne J., additional, Ansell, Stephen M., additional, Weiner, George J., additional, Wang, Alice H., additional, Witzig, Thomas E., additional, Dogan, Ahmet, additional, Slager, Susan L., additional, Habermann, Thomas M., additional, and Cerhan, James R., additional

Published
2012
Full Text
View/download PDF

22. Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Author

Shanafelt, Tait D., primary, Kay, Neil E., additional, Rabe, Kari G., additional, Inwards, David J., additional, Zent, Clive S., additional, Leis, Jose F., additional, Schwager, Susan M., additional, Thompson, Carrie A., additional, Bowen, Deborah A., additional, Witzig, Thomas E., additional, Slager, Susan L., additional, and Call, Timothy G., additional

Published
2011
Full Text
View/download PDF

23. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

Author

Mraz, Marek, primary, Zent, Clive S., additional, Church, Amy K., additional, Jelinek, Diane F., additional, Wu, Xiaosheng, additional, Pospisilova, Sarka, additional, Ansell, Stephen M., additional, Novak, Anne J., additional, Kay, Neil E., additional, Witzig, Thomas E., additional, and Nowakowski, Grzegorz S., additional

Published
2011
Full Text
View/download PDF

26. CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity

Author

Dronca, Roxana S., primary, Jevremovic, Dragan, additional, Hanson, Curtis A., additional, Rabe, Kari G., additional, Shanafelt, Tait D., additional, Morice, William G., additional, Call, Timothy G., additional, Kay, Neil E., additional, Collins, Charles S., additional, Schwager, Susan M., additional, Slager, Susan L., additional, and Zent, Clive S., additional

Published
2010
Full Text
View/download PDF

29. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression

Author

Ding, Wei, primary, Nowakowski, Grzegorz S., additional, Knox, Traci R., additional, Boysen, Justin C., additional, Maas, Mary L., additional, Schwager, Susan M., additional, Wu, Wenting, additional, Wellik, Linda E., additional, Dietz, Allan B., additional, Ghosh, Asish K., additional, Secreto, Charla R., additional, Medina, Kay L., additional, Shanafelt, Tait D., additional, Zent, Clive S., additional, Call, Timothy G., additional, and Kay, Neil E., additional

Published
2009
Full Text
View/download PDF

34. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Author

Zent, Clive S., primary, Ding, Wei, additional, Schwager, Susan M., additional, Reinalda, Megan S., additional, Hoyer, James D., additional, Jelinek, Diane F., additional, Tschumper, Renee C., additional, Bowen, Deborah A., additional, Call, Timothy G., additional, Shanafelt, Tait D., additional, Kay, Neil E., additional, and Slager, Susan L., additional

Published
2008
Full Text
View/download PDF

35. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

Author

Palmer, Shanique, primary, Hanson, Curtis A., additional, Zent, Clive S., additional, Porrata, Luis F., additional, LaPlant, Betsy, additional, Geyer, Susan M., additional, Markovic, Svetomir N., additional, Call, Timothy G., additional, Bowen, Deborah A., additional, Jelinek, Diane F., additional, Kay, Neil E., additional, and Shanafelt, Tait D., additional

Published
2008
Full Text
View/download PDF

36. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

Author

Shanafelt, Tait D., primary, Geyer, Susan M., additional, Bone, Nancy D., additional, Tschumper, Renee C., additional, Witzig, Tom E., additional, Nowakowski, Greg S., additional, Zent, Clive S., additional, Call, Tim G., additional, LaPlant, Betsy, additional, Dewald, Gordon W., additional, Jelinek, Diane F., additional, and Kay, Neil E., additional

Published
2008
Full Text
View/download PDF

37. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia

Author

Maddocks-Christianson, Kami, primary, Slager, Susan L., additional, Zent, Clive S., additional, Reinalda, Megan, additional, Call, Timothy G., additional, Habermann, Thomas M., additional, Bowen, Deborah A., additional, Hoyer, James D., additional, Schwager, Susan, additional, Jelinek, Diane F., additional, Kay, Neil E., additional, and Shanafelt, Tait D., additional

Published
2007
Full Text
View/download PDF

46. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Author

Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, and Kay NE

Subjects
Administration, Oral, Adult, Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Catechin administration & dosage, Catechin adverse effects, Catechin pharmacokinetics, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Lymphocyte Count, Male, Middle Aged, Neoplasm Staging, Treatment Outcome, Antineoplastic Agents administration & dosage, Asymptomatic Diseases, Catechin analogs & derivatives, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Abstract

Background: The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL)., Methods: Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 10(9) /L were eligible for this phase 2 trial. Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily., Results: A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months. Of these patients, 29 (69%) had Rai stage I to II disease. Patients received a median of 6 cycles of treatment (range, 1 cycle-6 cycles). The most common grade 3 side effects (according to National Cancer Institute Common Terminology Criteria for Adverse Events) were transaminitis (1 patient), abdominal pain (1 patient), and fatigue (1 patient). Clinical activity was observed, with 13 patients (31%) experiencing a sustained reduction of ≥ 20% in the ALC and 20 of 29 patients (69%) with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all lymph node areas. EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy (correlation co-efficient, 0.44; P = .02). Overall, 29 patients (69%) fulfilled the criteria for a biologic response with either a sustained decline ≥ 20% in the ALC and/or a reduction ≥ 30% in the sum of the products of all lymph node areas at some point during the 6 months of active treatment., Conclusions: Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial. Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients., (Copyright © 2012 American Cancer Society.)

Published
2013
Full Text
View/download PDF

47. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Author

Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, and Call TG

Subjects
Adult, Aged, Aged, 80 and over, Databases as Topic, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Male, Middle Aged, Prognosis, Clinical Competence, Hematology, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Medical Oncology
Abstract

Background: The impact of physicians' disease-specific expertise on patient outcome is unknown. Although previous studies suggest a survival advantage for cancer patients cared for at high-volume centers, these observations may simply reflect referral bias or better access to advanced technologies, clinical trials, and multidisciplinary support at large centers., Methods: We evaluated time to first treatment (TTFT) and overall survival (OS) of patients with newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) at a single academic center based on whether they were cared for by a hematologist/oncologist who subspecializes in CLL (CLL hematologist) or a hematologist/oncologist with expertise in other areas (non-CLL hematologist)., Results: Among 1309 newly diagnosed patients with CLL cared for between 1999 and 2009, 773(59%) were cared for by CLL hematologists and 536 were cared for by non-CLL hematologists. Among early-stage patients (Rai 0-I), median TTFT (9.2 vs 6.1 years; P < .001) and OS (10.5 years vs 8.8 years; P < .001) were longer for patients cared for by CLL hematologists. For all patients, OS was superior for patients cared for by CLL hematologists (10.5 years vs 8.4 years; P = .001). Physician's disease-specific expertise remained an independent predictor of OS after adjusting for age, sex, stage, and lymphocyte count at diagnosis. Patients seen by a CLL hematologist were also more likely to participate in clinical trials (48% vs 16%; P < .001)., Conclusions: Physician disease-specific expertise appears to influence outcome in patients with CLL. To the greatest extent possible, patients should be cared for by a hematologist/oncologist expert in the care of their specific malignancy. When not possible, practice guidelines developed by disease-specific experts should be followed., (Copyright © 2011 American Cancer Society.)

Published
2012
Full Text
View/download PDF

48. Validation of a new prognostic index for patients with chronic lymphocytic leukemia.

Author

Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, and Kay NE

Subjects
Aged, Humans, Middle Aged, Predictive Value of Tests, Prognosis, Reproducibility of Results, Survival Analysis, Health Status Indicators, Leukemia, Lymphocytic, Chronic, B-Cell mortality
Abstract

Background: The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. A prognostic index based on widely available clinical and laboratory features was recently developed to predict survival among patients with previously untreated CLL. This index requires validation in an independent series of patients before widespread use can be recommended., Methods: The Mayo Clinic CLL database was used to evaluate the validity and reproducibility of the new prognostic index., Results: A total of 440 patients with newly diagnosed CLL who were seen at the Mayo Clinic within 12 months of diagnosis and for whom data were available with which to calculate index score were identified. Patients were classified as low, intermediate, or high risk using the prognostic index. The estimated median survival times were: not reached for low risk, 10.1 years for intermediate risk, and 7.2 years for high risk. The estimated median and 5-year survival by prognostic index risk category were similar to those originally reported. The prognostic index risk category added predictive value beyond that of Rai risk alone (P=.004). The prognostic index risk category remained a predictor of survival when analysis was limited to Rai stage 0 (P=.03) and nonreferred patients (P<.0001) and also predicted time to treatment (P<.0001)., Conclusions: The results of the current study confirm the ability of a newly developed prognostic index to predict survival among patients with previously untreated CLL. The study also extended the utility of the index by demonstrating that it is useful at diagnosis, retains prognostic value when applied exclusively to Rai stage 0 patients, is effective in nonreferred patients, and predicts time to treatment., (Copyright (c) 2009 American Cancer Society.)

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results